Chemotherapy News and Research

Latest Chemotherapy News and Research

Spectrum Pharmaceuticals begins Phase 2 clinical program for SPI-2012

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has initiated a Phase 2 clinical program for SPI-2012 (also referred to as "LAPS-GCSF"), a drug candidate for the treatment of chemotherapy-induced neutropenia that utilizes partner Hanmi Pharmaceutical Company's proprietary LAPSCOVERY™ Technology.

8 Apr 2013

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

NewLink Genetics Corporation, a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that the company presented preclinical data for NLG919, a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, at the American Association for Cancer Research 2013 annual meeting.

8 Apr 2013

Berg to present new findings on cancer treatment, Interrogative Biology Platform at AACR meeting

Berg - a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach - announced today that it will be presenting four abstracts at the AACR Annual Meeting 2013, in Washington, D.C.

8 Apr 2013

One cohort of Phase 2 NSCLC study fails to meet primary endpoint, Merrimack says

Merrimack Pharmaceuticals, Inc. today announced that one cohort of a Phase 2 non-small cell lung cancer study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with erlotinib to treat patients with NSCLC whose disease progressed on an anti-EGFR tyrosine kinase inhibitor (EGFR-TKI).

5 Apr 2013

UNC study shows promise for uncovering true mechanisms of human stem cell biology

For the first time, researchers at the University of North Carolina at Chapel Hill have isolated adult stem cells from human intestinal tissue.

5 Apr 2013

Medicare misperceptions create tougher task for lawmakers

The New York Times reports that public misunderstandings about the specifics of entitlement benefits make trimming Medicare spending more difficult. Meanwhile, Politico reports on an idea that might bridge the partisan divide that plagues these efforts.

5 Apr 2013

Wistar scientists describe mechanics of oncogene-induced senescence

Researchers from The Wistar Institute explain a new molecular mechanism behind the phenomenon of oncogene-induced senescence. By depriving the cell of the ability to make new nucleotides-the building blocks of DNA molecules-cells can suppress cancer development by forcing a damaged cell into a senescent state, where the cell remains alive yet cannot reproduce.

5 Apr 2013

First Edition: April 4, 2013

Kaiser Health News staff writer Julie Appleby, working in collaboration with USA Today, reports: "It's not just sore throats and flu shots anymore. Walgreens today became the first retail store chain to expand its health care services to include diagnosing and treating patients for chronic conditions such as asthma, diabetes and high cholesterol. The move is the retail industry's boldest push yet into an area long controlled by physicians, and comes amid continuing concerns about health care costs and a potential shortage of primary care doctors" (Appleby, 4/4).

4 Apr 2013

Scientists develop new cancer immunotherapy treatment for children with high-risk solid tumors

Recently, research using adoptive T-cell immunotherapy in blood cancers have shown success, most notably in the case of a seven-year-old girl whose leukemia went into remission using altered T-cells and a disabled HIV virus.

4 Apr 2013

Molecular diagnostic testing in lung cancer offers new hope for patients

The emergence of molecular diagnostic testing in lung cancer offers new hope for patients battling the number one cancer killer in the United States and abroad.

4 Apr 2013

Duloxetine drug alleviates pain from chemotherapy

Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April 3 issue of JAMA.

3 Apr 2013

Polymer scaffolds can advance the development of cancer therapeutics

Porous polymer scaffolds fabricated to support the growth of biological tissue for implantation may hold the potential to greatly accelerate the development of cancer therapeutics.

3 Apr 2013

CRG researchers reprogramme lymphoma and leukaemia cells to halt malignancy

Researchers from the Centre for Genomic Regulation (CRG) in Barcelona reprogramme lymphoma and leukaemia cells to halt their malignancy. Resulting cells remain benign even when no longer subjected to treatment and reduce likelihood of developing new tumours.

3 Apr 2013

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

3 Apr 2013

Doctors give new hope for leukemia patients

Leukemia patients receive a bone marrow transplant, which allows them to build a "new" immune system. However, this immune system not only attacks cancer cells but healthy tissue too.

3 Apr 2013

Researchers develop new guidelines to treat recently diagnosed multiple myeloma patients

Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to follow recommendations for providing initial therapy, stem cell transplant and maintenance therapy.

2 Apr 2013

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer.

2 Apr 2013

Study links mutated histone protein to rare brain stem cancer in children

Most cancer treatments are blunt. In an attempt to eradicate tumors, oncologists often turn to radiation or chemotherapy, which can damage healthy tissue along with the cancerous growths.

2 Apr 2013

Looking good helps women cancer patients feel better, gives more confidence to cope with disease

A year ago, Colleen Williams was into the natural look. She seldom bothered to put on makeup and she let her long, wavy, brown hair flow free. Cancer treatment changed that. These days, when she feels well enough to go to work, Williams wears her "cute hat" to cover her newly-balding head and takes a little extra time in the morning to pencil in her thinning brows and apply concealer to make her skin look a little less gray.

30 Mar 2013

Phase 2 study of REOLYSIN meets primary endpoint in patients with squamous cell lung cancer

Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).

28 Mar 2013

Chemotherapy News and Research

Latest Chemotherapy News and Research

Spectrum Pharmaceuticals begins Phase 2 clinical program for SPI-2012

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

Berg to present new findings on cancer treatment, Interrogative Biology Platform at AACR meeting

One cohort of Phase 2 NSCLC study fails to meet primary endpoint, Merrimack says

UNC study shows promise for uncovering true mechanisms of human stem cell biology

Medicare misperceptions create tougher task for lawmakers

Wistar scientists describe mechanics of oncogene-induced senescence

First Edition: April 4, 2013

Scientists develop new cancer immunotherapy treatment for children with high-risk solid tumors

Molecular diagnostic testing in lung cancer offers new hope for patients

Duloxetine drug alleviates pain from chemotherapy

Polymer scaffolds can advance the development of cancer therapeutics

CRG researchers reprogramme lymphoma and leukaemia cells to halt malignancy

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

Doctors give new hope for leukemia patients

Researchers develop new guidelines to treat recently diagnosed multiple myeloma patients

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

Study links mutated histone protein to rare brain stem cancer in children

Looking good helps women cancer patients feel better, gives more confidence to cope with disease

Phase 2 study of REOLYSIN meets primary endpoint in patients with squamous cell lung cancer

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in